Durvalumab (MEDI 4736) 是一种人源化的抗 PD-L1 蛋白单克隆抗体。Durvalumab (MEDI 4736) 完全阻断 PD-L1 与 PD-1 和 CD80 结合， IC₅₀ 分别为 0.1 和 0.04 nM。

Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC 50 s of 0.1 and 0.04 nM, respectively.

Liquid

IC50: 0.1 nM (PD-L1/PD-1), 0.04 nM (PD-L1/CD80)

Durvalumab inhibits tumor growth in mouse xenograft models of human melanoma (A375) and pancreatic (HPAC) tumour cell lines, via a T-cell-mediated mechanism. Durvalumab (5-0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5-0.1 mg/kg for NOD/SCID mice with A375 tumor; administration i.p.; twice per week; for 3 weeks) significantly inhibits the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody. Tumor growth inhibition of the HPAC cells reaches 74%, whereas inhibition of the A375 cells reaches 77%. When administered in the absence of T cells, Durvalumab has no effect on the growth of the A375 tumor xenograft. has not independently confirmed the accuracy of these methods. They are for reference only.

Please store the product under the recommended conditions in the Certificate of Analysis.

[1]. Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215.
[2]. Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep;3(9):1052-62.